• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.纳武单抗治疗复发多发性骨髓瘤后立即进行治疗的疗效和毒性
Leuk Lymphoma. 2018 Jan;59(1):221-224. doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30.
2
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.复发/难治性骨髓瘤患者接受有限疗程双特异性抗体治疗后的持续缓解
Blood Cancer J. 2024 Aug 12;14(1):137. doi: 10.1038/s41408-024-01114-7.
3
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.采用不同 BCMA 靶向疗法对复发/难治性多发性骨髓瘤进行序贯治疗。
Blood Adv. 2019 Aug 27;3(16):2487-2490. doi: 10.1182/bloodadvances.2019000466.
4
Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.局部放疗后纳武利尤单抗治疗肺多形性癌伴术后快速进展性复发的显著疗效。
Thorac Cancer. 2019 May;10(5):1263-1266. doi: 10.1111/1759-7714.13029. Epub 2019 Mar 12.
5
Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events.由于免疫相关不良反应而停用纳武利尤单抗单药治疗后复发和/或转移性头颈部癌症患者的临床结局。
Acta Otolaryngol. 2020 Dec;140(12):1043-1048. doi: 10.1080/00016489.2020.1807601. Epub 2020 Aug 18.
6
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.纳武利尤单抗治疗不符合条件或自体移植失败的复发/难治性弥漫性大 B 细胞淋巴瘤患者：一项单臂、二期研究。
J Clin Oncol. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.
7
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.本妥昔单抗联合纳武利尤单抗用于老年或不符合化疗条件的霍奇金淋巴瘤患者的一线治疗（ACCRU）：一项多中心、单臂、2期试验
Lancet Haematol. 2020 Nov;7(11):e808-e815. doi: 10.1016/S2352-3026(20)30275-1. Epub 2020 Oct 1.
8
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.伊匹木单抗、纳武单抗和本妥昔单抗联合疗法用于复发或难治性霍奇金淋巴瘤患者：一项开放标签、多中心、1/2期试验的1期结果
Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0.
9
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.确认：一项双盲、安慰剂对照的III期临床试验，研究纳武单抗对复发间皮瘤患者的疗效：一项随机对照试验的研究方案
Trials. 2018 Apr 18;19(1):233. doi: 10.1186/s13063-018-2602-y.
10
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.纳武利尤单抗联合 AVd 方案治疗早期不良预后经典型霍奇金淋巴瘤的疗效：德国霍奇金研究组 NIVAHL 随机 2 期试验。
JAMA Oncol. 2020 Jun 1;6(6):872-880. doi: 10.1001/jamaoncol.2020.0750.

引用本文的文献

1
Identification of an angiogenesis-related risk score model for survival prediction and immunosubtype screening in multiple myeloma.鉴定多发性骨髓瘤生存预测和免疫亚型筛选的血管生成相关风险评分模型。
Aging (Albany NY). 2024 Feb 5;16(3):2657-2678. doi: 10.18632/aging.205502.
2
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.高表达的 NEK2 在髓系祖细胞中抑制多发性骨髓瘤中的 T 细胞免疫。
Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3.
3
Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient.纳武单抗对一名多原发性癌症患者的胃癌和肺癌有效，但对多发性骨髓瘤无效。
Case Rep Hematol. 2021 Aug 26;2021:9965371. doi: 10.1155/2021/9965371. eCollection 2021.
4
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.意义未明单克隆丙种球蛋白血症和多发性骨髓瘤的淋巴细胞亚群和炎症细胞因子。
Int J Mol Sci. 2019 Jun 10;20(11):2822. doi: 10.3390/ijms20112822.
5
The challenges of checkpoint inhibition in the treatment of multiple myeloma.在多发性骨髓瘤治疗中抑制检查点所面临的挑战。
Cell Immunol. 2018 Dec;334:87-98. doi: 10.1016/j.cellimm.2018.10.003. Epub 2018 Oct 13.
6
Cancer immune therapy for lymphoid malignancies: recent advances.恶性淋巴瘤的肿瘤免疫治疗：最新进展。
Semin Immunopathol. 2019 Jan;41(1):111-124. doi: 10.1007/s00281-018-0696-7. Epub 2018 Jul 13.
7
Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.淋巴瘤和骨髓瘤的免疫治疗：现状与展望。
Clin Cancer Res. 2018 Mar 1;24(5):1002-1010. doi: 10.1158/1078-0432.CCR-17-0539. Epub 2017 Sep 12.

本文引用的文献

1
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.纳武利尤单抗治疗复发或难治性血液系统恶性肿瘤患者：Ib期研究的初步结果
J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.
2
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.高危细胞遗传学特征的多发性骨髓瘤的治疗：国际骨髓瘤工作组共识
Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21.
3
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.多发性骨髓瘤中的免疫反应：天然免疫监视的作用及免疫疗法的潜力
Cell Mol Life Sci. 2016 Apr;73(8):1569-89. doi: 10.1007/s00018-016-2135-z. Epub 2016 Jan 22.
4
Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.单克隆丙种球蛋白病中抗原特异性免疫、干细胞抗原和免疫检查点的前瞻性分析。
Blood. 2015 Nov 26;126(22):2475-8. doi: 10.1182/blood-2015-03-632919. Epub 2015 Oct 14.
5
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.自体移植后多发性骨髓瘤复发时 T 细胞耗竭：免疫治疗的最佳时机。
Cancer Immunol Res. 2016 Jan;4(1):61-71. doi: 10.1158/2326-6066.CIR-15-0055. Epub 2015 Oct 13.
6
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.依鲁替尼联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项多中心、开放标签的 II 期研究
N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.
7
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.关于宽容度降低：通过靶向检查点和 T 细胞激活激动剂增强癌症免疫监视。
Sci Transl Med. 2015 Mar 25;7(280):280sr1. doi: 10.1126/scitranslmed.3010274.
8
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤的 PD-1 阻断作用。
N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.
9
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.埃罗妥珠单抗用于晚期多发性骨髓瘤患者的1期多中心开放标签剂量递增研究。
Blood. 2012 Jul 19;120(3):552-9. doi: 10.1182/blood-2011-06-360552. Epub 2011 Dec 19.
10
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.统一临床试验报告的共识建议：国际骨髓瘤工作组共识小组报告 1.
Blood. 2011 May 5;117(18):4691-5. doi: 10.1182/blood-2010-10-299487. Epub 2011 Feb 3.

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

作者信息

Pianko Matthew J, Funt Samuel A, Page David B, Cattry Deepika, Scott Emma C, Ansell Stephen M, Borrello Ivan M, Gutierrez Martin, Lendvai Nikoletta, Hassoun Hani, Landgren C Ola, Lesokhin Alexander M

机构信息

a Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center , New York , NY , USA.

b Providence Cancer Center, Earle A. Chiles Research Institute Portland , OR , USA.

出版信息

Leuk Lymphoma. 2018 Jan;59(1):221-224. doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30.

DOI:10.1080/10428194.2017.1320713
PMID:28554253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5645787/
Abstract
摘要